BOSTON--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) today announced that the Company has entered into a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Agriculture, Agricultural Research Service (USDA, ARS) for further optimization of HepaLife’s PICM-19 liver stem cell line for application in the first-of-its-kind bioartificial liver device.
